His research career has focused on Duchenne muscular dystrophy (DMD), the most common and serious form of childhood muscle wasting, which arises from mutations in the dystrophin gene.
Along with this research partner Professor Sue Fletcher, his insights into the cause of DMD have led to an innovative treatment where the first of a series of drugs has just been granted accelerated approval by the US Food and Drug Administration (FDA).
This mutation specific approach promises to revolutionise treatments for DMD and many other genetic diseases.
In September 2016, the FDA approved the development of Exondys 51, a drug developed by Professors Wilton and Fletcher which has drastically improved the health and wellbeing of DMD sufferers during clinical trials.
Over the past twenty-five years, Professor Wilton and his team have made significant discoveries in their gene research and his work has been recognised with the 2012 Western Australian Innovator of the Year award; the 2013 Australian Museum Eureka Award for Translational Medicine; the 2014 LabGear Australia Discovery award.
Most recently, he was a finalist in the 2016 Western Australian of the Year (professions category).
Professor Wilton’s TEDx presentation can be viewed here.